Cardio Catch-Up: Boston Scientific's Farapulse PFA Shows Short Learning Curve In European Registry
Executive Summary
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. This edition recaps the presentation of results from EU PORIA, a European registry atrial fibrillation patients treated with Boston Scientific's Farapulse pulsed field ablation system.
You may also be interested in...
Boston Scientific Prepares For PFA Race In US And Asia
The FDA approved Boston Scientific’s Farapulse pulsed field ablation system, as expected, at the end of January, and the company believes regulators in China and Japan will approve it later this year. Brad Sutton, Boston Scientific’s chief medical officer for atrial fibrillation solutions, told Medtech Insight why PFA will soon dominate the atrial fibrillation ablation market and how his company plans to be a leader in PFA.
News We’re Watching: Philips And Walgreens Settlements, ReCor Readies For Takeoff, Farapulse Trial Results
This week, Philips announced a legal settlement on recalled CPAPs and BiPAPs; the FDA released emergency preparation recommendations; ReCor prepared to bring Paradise RDN to the US market; and Abbott released the results of a trial comparing optical coherence tomography (OCT) to angiography for guidance during cardiac surgery.
Cardio Catch-Up: Trial Of Biosense Webster’s Dual-Energy Ablation System Finishes Enrollment
On 19 July, Biosense Webster announced the final enrollment in the SmartfIRE trial of its Thermocool Smarttouch SF cardiac ablation catheter with the Trupulse generator and Carto imaging system.